Skip to content
OpenCapital
Get started

Arcus Biosciences RCUS Market capitalization

Market capitalization at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$123.83B-0.2%
Merck & Co. logo
Merck & Co.MRK
$297.4B+31.2%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$81.68B+17.8%
AbbVie logo
AbbVieABBV
$384.69B+3.8%
Immunome logo
ImmunomeIMNM
$2.47B+323%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$2.93B+104%

Other financials

Income statement

See full
Revenue$17.0M-39.3%
Operating income-$134.0M-9.8%
Net income-$128.0M-14.3%
EPS (diluted)-$1.02+10.5%

Balance sheet

See full
Cash & equivalents$201.0M+4.7%
Total debt$113.0M+88.3%
Total equity$524.0M-1.3%
Total assets$997.0M-13.8%

Cash flow

See full
Operating cash flow-$138.0M-4.5%
CapEx--100%
Free cash flow-$138.0M-3.8%

Valuation

See full
Enterprise value$3.46B+275%
P/S15×+7.3×

Profitability

See full
Operating margin-168.6%-52.7pp
Net margin-156.4%-47.5pp
FCF margin-207.2%—

Returns & leverage

See full
Return on equity-70%+8.4pp
Debt / equity0.2×+0.1×
Current ratio4×-1.3×

Where this comes from

Computed from the period-end share price: $2.71B.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's market capitalization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcus Biosciences's market capitalization?
Arcus Biosciences (RCUS) reported market capitalization of $2.71B in Q1 2026.
How has Arcus Biosciences's market capitalization changed year-over-year?
Arcus Biosciences's market capitalization increased by 225.9% year-over-year, from $830.86M to $2.71B.
What is the long-term trend for Arcus Biosciences's market capitalization?
Over 5 years (2020 to 2025), Arcus Biosciences's market capitalization has grown at a 10.1% compound annual growth rate (CAGR), from $1.82B to $2.95B.
What does market capitalization mean?
The total market value of the company's equity at the quarter end (share price × shares outstanding), sampled from daily market data. The latest point tracks the live price.